Fierce competition expected among hepatitis C therapies, triggered by Zepatier’s approval

Another competitor showed up in the Korean hepatitis C therapy market where Gilead and BMS are competing each other.

According to the industry concerned on the 22^nd, the Korea MSD’s hepatitis C therapy ‘Zepatier(elbasvir/grazoprevir)’ recently acquired approval from the Ministry of Food and Drug Safety(MFDS), setting up a time to launch in Korea.

Zepatier was approved to be used alone or with...